SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-24-115940
Filing Date
2024-04-26
Accepted
2024-04-26 08:32:58
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A d797640ddefa14a.htm DEFA14A 26529
2 GRAPHIC g797640dspe.jpg GRAPHIC 920
3 GRAPHIC g797640g99n27.jpg GRAPHIC 143165
4 GRAPHIC g797640g99n30.jpg GRAPHIC 105226
5 GRAPHIC g797640g99n31.jpg GRAPHIC 10764
  Complete submission text file 0001193125-24-115940.txt   386343
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36483 | Film No.: 24879011
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)